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Abstract Docosahexaenoic acid (DHA) is enriched in mem-
brane phospholipids of the central nervous system (CNS) and
has a role in aging and neuropsychiatric disorders. DHA is
metabolized by the enzyme Alox15 to 17S-hydroxy-DHA,
which is then converted to 7S-hydroperoxy,17S-hydroxy-
DHA by a 5-lipoxygenase, and thence via epoxy intermediates
to the anti-inflammatory molecule, resolvin D1 (RvD1 or
7S,8R,17S-trihydroxy-docosa-Z,9E,11E,13Z,15E,19Z-
hexaenoic acid). In this study, we investigated the distribution
and function of Alox15 in the CNS. RT-PCR of the CNS
showed that the prefrontal cortex exhibits the highest Alox15
mRNA expression level, followed by the parietal associa-
tion cortex and secondary auditory cortex, olfactory bulb,
motor and somatosensory cortices, and the hippocampus.
Western blot analysis was consistent with RT-PCR data, in
that the prefrontal cortex, cerebral cortex, hippocampus, and
olfactory bulb had high Alox15 protein expression.
Immunohistochemistry showed moderate staining in the ol-
factory bulb, cerebral cortex, septum, striatum, cerebellar
cortex, cochlear nuclei, spinal trigeminal nucleus, and dorsal
horn of the spinal cord. Immuno-electron microscopy
showed localization of Alox15 in dendrites, in the
prefrontal cortex. Liquid chromatography mass spectrometry
analysis showed significant decrease in resolvin D1 levels
in the prefrontal cortex after inhibition or antisense knock-
down of Alox15. Alox15 inhibition or antisense knockdown
in the prefrontal cortex also blocked long-term potentiation
of the hippocampo-prefrontal cortex pathway and increased
errors in alternation, in the T-maze test. They indicate that
Alox15 processing of DHA contributes to production of
resolvin D1 and LTP at hippocampo-prefrontal cortical
synapses and associated spatial working memory perfor-
mance. Together, results provide evidence for a key role
of anti-inflammatory molecules generated by Alox15 and
DHA, such as resolvin D1, in memory. They suggest that
neuroinflammatory brain disorders and chronic neurode-
generation may ‘drain’ anti-inflammatory molecules that
are necessary for normal neuronal signaling, and compro-
mise cognition.
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Introduction
Lipoxygenases (EC 1.13.11) are a superfamily of oxidoreductive
enzymes that contain a nonheme iron and catalyze the incorpo-
ration of two atoms of oxygen into a single donor, specifically
polyunsaturated fatty acids (PUFA) containing a cis,cis-1,4-
pentadiene structure [1, 2]. The dioxygenation of PUFAs such
as docosahexaenoic acid (DHA) and arachidonic acid (AA) by
lipoxygenases generates fatty acid hydroperoxy products [1, 3].
Of the lipoxygenases, 15-lipoxygenase catalyzes the direct
dioxygenation of phospholipids and cholesterol esters of biolog-
ical membranes and plasma lipoproteins [4]. There are two iso-
forms of the 15-lipoxygenase enzyme, the type 1 (Alox15), also
known in rodents as leukocyte-type and in humans as reticulo-
cyte-type, and type 2 (Alox15B) [5], both of which regulate the
production of fatty acid hydroperoxides [6, 7]. Human
reticulocyte-type Alox15, also known as arachidonate 15-
lipoxygenase (Alox15), is a 75 kDa enzyme made up of a single
chain of amino acids. The Alox15 gene is found on human
chromosome 17. It has 10 tandem repeats of a motif rich in
pyrimidine in its 3′-untranslated region, which regulate enzyme
expression inhibiting Alox15 translation through association
with the regulatory proteins, heterogeneous ribonucleoprotein
K, and heterogeneous ribonucleoprotein E1 [8].
Alox15 metabolizes DHA to 17S-hydroxy-DHA, which is
then converted to 7S-hydroperoxy,17S-hydroxy-DHA by a 5-
lipoxygenase, and thence via epoxy intermediates to resolvin
D1 (RvD1 o r 7S , 8R , 1 7S - t r i h y d r o x y - d o c o s a -
Z,9E,11E,13Z,15E,19Z-hexaenoic acid) and resolvin D2
( R vD 2 o r 7 S , 1 6 R , 1 7 S t r i h y d r o x y - d o c o s a -
4Z,8E,10Z,12E,14E,19Z-hexaenoic acid) [9]. The Alox15 prod-
uct 17S-hydroxy-DHA can also be converted to a 16(17)-epox-
ide and then to the 10,17-dihydroxy docosatriene termed
neuroprotectin D1 (NPD1) [9]. These lipid mediators are in-
volved in the removal of inflammatory cells and restoration of
tissue integrity during resolution of inflammation [10]. They can
modulate the effects of proinflammatory eicosanoids derived
from AA [11], reduce leukocyte trafficking, and downregulate
cytokine expression [11]. Alox15 also plays a role in supraspinal
antinociception originating in the prefrontal cortex [12], but thus
far, little is known about the distribution and function of the
enzyme in the CNS.
The hippocampus and prefrontal cortex function together
jointly as a memory system enabling working memory and
consolidation of contextual information [13]. DHA and its
docosanoids are beneficial for these cognitive functions [14].
DHA, which is a substrate of Alox15, is enriched in mem-
brane phospholipids of the central nervous system (CNS)
[15], and disturbances in its metabolism could play a role in
aging and neuropsychiatric disorders [15–17]. DHA is re-
leased from membrane phospholipids by calcium-
independent phospholipase A2 (iPLA2) [18–21]. Decreased
iPLA2 activity has been detected in the prefrontal cortex of
patients with Alzheimer’s disease (AD) [22]. iPLA2 plays a
role in synaptic plasticity, and inhibition or antisense oligonu-
cleotide knockdown of iPLA2 prevents induction of
hippocampo-prefrontal cortex long-term potentiation (LTP)
[23]. Selective inhibitors of iPLA2 prevent induction of LTP
in hippocampal slices [24]. DHA rescues the impairment
caused by an iPLA2 inhibitor [25, 26] while its supplementa-
tion improves learning and memory in patients with age-
related cognitive decline [27] and protects from amyloid and
dendritic pathology in AD model mice [28–30].
We hypothesize that DHA and its metabolites that are pro-
duced by the action of iPLA2 are important for hippocampo-
prefrontal cortex synaptic plasticity and prefrontal cortex-
dependent working memory. The present study was carried
out to elucidate the relative expression of Alox15 across brain
regions and its possible role in prefrontal cortical function.
Methods and Materials
Animals
Adult male Wistar rats (250–300 g) were purchased from
InVivos, Singapore, and housed in temperature controlled
(23 ± 1 °C), individually ventilated cages on a 12-h light-dark
cycle (7AM–7PM) with access to food and water. Rats were
acclimatized for 4 days before the start of experiments. All
procedures were in accordance with the Principles of
Laboratory Animal Care and approved by the Institutional
Animal Care and Use Committee of the National University
of Singapore.
Chemicals
The specific Alox15 inhibitor, PD146176, was purchased
from Cayman Chemicals (Ann Arbor, Michigan, USA) and
was diluted in the vehicle dimethyl sulfoxide (DMSO)
(Sigma, St. Louis, USA).
Antisense Oligonucleotide
The antisense oligonucleotide used was a 16-base oligonucle-
otide (5′-CACATGGTGATGAAGT-3′). This has been shown
to effectively knock down Alox15 expression in the mouse
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brain [12], but is also suitable for the rat brain. Scrambled
sense oligonucleotide was used as a control (5′-CACG
TCTATACACCAC-3′). Both antisense and sense oligonucle-
otides contained phosphorothioate linkages to prevent nucle-
ase degradation (IBA, Germany). Solutions of 200 μM were
prepared by dissolving lyophilized material in nuclease-free
water.
Stereotaxic Injection
Rats were anesthetized with the inhalational anesthetic
isoflurane (Sigma-Aldrich, St Louis, USA)—up to 5% for
induction, 1–3% for maintenance using a precision vaporizer
and mounted on a stereotaxic frame (Stoelting, Wood Dale,
USA). A midline incision was made on the scalp and small
craniotomies performed over the injection sites, 4.0 mm ante-
rior and 1.5 mm lateral to the bregma on both sides, and
2.0 mm from the surface of the cortex. These coordinates
correspond to the prefrontal cortex and were determined using
the rat brain atlas of Paxinos and Watson 1998 [31]. Five
microliters of either vehicle control (DMSO) or Alox15 inhib-
itor in DMSO (40 mM) and 2 μl of antisense oligonucleotide
or scrambled sense oligonucleotide were bilaterally injected
into the cortex, at a rate of 5 min per injection. Injections were
carried out in a blinded manner to reduce experimenter bias.
Real-Time Reverse Transcriptase Polymerase Chain
Reaction
Six adult male Wistar rats were used per experiment for this
portion of the study. Rats were deeply anesthetized with a
ketamine/xylazine cocktail and sacrificed by decapitation.
The ketamine/xylazine mixture used was prepared in saline
[32] (7.5 ml ketamine (75 mg/kg), 5 ml xylazine (10 mg/kg),
in 7.5-ml 0.9% sodium chloride solution). Ketamine used was
obtained from Parnell Manufacturing Pte Ltd., Alexandria,
New South Wales, Australia, while xylazine used was obtain-
ed from Ilium Xylazil, Troy Laboratories Pty Ltd.,
Glendenning, New South Wales, Australia. Various parts of
the rat brain including olfactory bulb, prefrontal cortex, cortex
1, cortex 2, striatum, thalamus/hypothalamus, hippocampus,
cerebellum, and brainstem were dissected out, immersed in
RNAlater® solution (Ambion, TX, USA), and snap frozen
in liquid nitrogen. Anatomically, cortex 1 contains the primary
and secondary motor cortex and the primary somatosensory
cortex, whereas cortex 2 includes the parietal association cor-
tex and secondary auditory cortex.
Total RNAwas extracted using Trizol reagent (Invitrogen,
CA, USA) according to (manufacturer’s) protocol. RNeasy®
Mini Kit (Qiagen, Inc., CA, USA) was used to purify the
RNA. Samples were reverse transcribed using HighCapacity
cDNA Reverse Transcription Kits (Applied Biosystems, CA,
USA). Reaction conditions were 25 °C for 10 min, 37 °C for
120 min, and 85 °C for 5 s. Real-time PCR amplification was
performed using a 7500 Real-time PCR system (Applied
Biosystems) with TaqMan® Universal PCR Master Mix
(Applied Biosystems), Alox5 (Rn00563172_m1), Alox12
(Rn01461082_m1), Alox15 (Rn00696151_m1), and β-actin
probes (#4352340E) (Applied Biosystems, CA, USA) accord-
ing to the manufacturer’s instructions. The PCR conditions
were as follows: incubation at 50 °C for 2 min and 95 °C for
10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for
1 min. All reactions were carried out in triplicate. The thresh-
old cycle (CT) was measured as the number of cycles in which
the reporter fluorescence emission exceeds the preset thresh-
old level. Amplified transcripts were quantified using the
comparative CTmethod [33], with the formula for relative fold
change =2−ΔΔCT. The mean and standard error were then
calculated.
Western Blot
Six adult maleWistar rats were used for the first portion of this
study. Rats were deeply anesthetized with a ketamine/xylazine
cocktail and sacrificed by decapitation. Various parts of the rat
brain including olfactory bulb, prefrontal cortex, striatum,
thalamus/hypothalamus, hippocampus, cerebellum,
brainstem, and spinal cord were dissected out and snap frozen
in liquid nitrogen.
Four adult maleWistar rats were used per group (scrambled
sense and Alox15 antisense) for the second portion of this
study. Rats that had been stereotaxically injected with scram-
bled sense or antisense oligonucleotides were deeply anesthe-
tized with the ketamine/xylazine cocktail and sacrificed by
decapitation 4 days after stereotaxic injection. The prefrontal
cortices of these rats were dissected out and snap frozen in
liquid nitrogen.
Tissues were homogenized using a Tissue Tearor®
(Biospec, ITS Science and Medical, Singapore) in ice-
cold buffer (M-Per mammalian protein extraction kit,
1 mM EDTA and 0.25 mM DTT). Homogenates were
centrifuged at 13,000 rpm for 20 min, and the super-
natant collected. Protein concentration in the superna-
tant was determined using a Bio-Rad protein assay kit
(Bio-Rad Laboratories, Hercules, USA). Proteins were
resolved in 15% sodium dodecyl sulfate polyacryl-
amide gel (SDS-PAGE) under reducing conditions
and subsequently electrotransferred to a PVDF mem-
brane (Amersham Pharmacia Biotech, Little Chalfont,
UK). The molecular weights of the proteins were de-
termined using a Bio-Rad Prestained Protein Ladder
(Bio-Rad Laboratories). Non-specific binding sites on
the PVDF membrane were blocked by incubation with
5% non-fat milk in Tris-buffered saline-Tween (TBST)
for 1 h. The PVDF membrane was then incubated
o v e r n i g h t w i t h a n a f f i n i t y - p u r i f i e d mo u s e
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monoclonal antibody to Alox15 (Abcam, Cambridge,
UK, diluted 1:2000) in TBST with 5% non-fat milk.
The membrane was then washed in TBST and incu-
bated with horseradish peroxidase conjugated horse
anti-mouse IgG (ThermoFisher Scientific, Waltham,
USA, diluted 1: 2000) for 1 h at room temperature.
Immunoreactivity was visualized using an enhanced
chemiluminescence kit (Pierce, Rockford, USA) ac-
cording to the manufacturer’s instructions. Band inten-
sities were quantified by densitometric analysis.
Immunohistochemistry
Four adult male Wistar rats were used in this portion of
the study. Rats were deeply anesthetized and perfused
through the left cardiac ventricle with a solution of 4%
paraformaldehyde and 0.1% glutaraldehyde in 0.1 M
phosphate buffer (pH 7.4). The brains were removed and
sectioned coronally at 100 μm using a vibrating micro-
tome. Sections were washed 30 times for 5 min each with
phosphate-buffered saline (PBS) and incubated overnight
with an affinity-purified mouse monoclonal antibody to
Alox15 (Abcam, Cambridge, UK), diluted 1:50 in PBS.
Sections were incubated for 1 h in a 1:100 dilution of
biotinylated horse anti-mouse IgG (Vector, Burlingame,
CA), reacted for 1 h with avidin-biotinylated horseradish
peroxidase complex, and visualized by treatment for
22 min in 0.05% 3,3-diaminobenzidine tetrahydrochloride
solution in Tris buffer containing 0.05% hydrogen perox-
ide. Some sections were mounted on glass slides and
counterstained with methyl green and visualized with a
light microscope. The remaining sections were processed
for electron microscopy.
Electron Microscopy
Electron microscopy was carried out by subdissecting immu-
nostained sections of the prefrontal cortex into smaller rectan-
gular portions (1.0 × 1.5 mm). Samples were osmicated for 1 h
in osmium tetroxide (OsO4), washed in distilled water for
20 min, then dehydrated in an ascending series of ethanol
and acetone as follows: 25% ethanol, 3 min; 50% ethanol,
5 min; 75% ethanol, 5 min; 95% ethanol, 5 min; 100% etha-
nol, 5 min; 100% acetone, 5 min × 2, then embedded in
Araldite. Thin sections were obtained from the first 5 μm of
the sections, mounted on copper grids coated with Formvar,
and stained with lead citrate. They were viewed using a JEOL
1010EX electron microscope.
Liquid Chromatography Mass Spectrometry
Six adult male Wistar rats were used per group (vehicle
control and Alox15 inhibitor) in the first portion of this
study. Rats were stereotaxically injected with 5 μl of
either vehicle control (DMSO) or Alox15 inhibitor in
DMSO (40 mM) bilaterally at a rate of 5 min per in-
jection as described above. After a 1-day time point,
rats were deeply anesthetized with the ketamine/
xylazine cocktail and sacrificed by decapitation. The
prefrontal cortex of these rats was removed and snap
frozen in liquid nitrogen.
Six adult male Wistar rats were used per group (saline,
Alox15 scrambled sense, and Alox15 antisense) in the second
portion of this study. Rats were stereotaxically injected with
either scrambled sense oligonucleotide, Alox15 antisense oli-
gonucleotide, or saline bilaterally at a rate of 5 min per injec-
tion as described above. The prefrontal cortex was removed
and snap frozen in liquid nitrogen.
Tissues were homogenized in 750 μl of Folch solution
(2:1 v/v chloroform/methanol) using a Tissue Tearor™
(Biospec, USA). Samples were then sonicated for 30 min at
4 °C. A total of 200 μl of 0.88% KCl was added to each
sample. Samples were vortexed for 1 min, then centrifuged
at 9000g for 2 min, and the organic portions collected and
vacuum-dried (Thermo Savant SpeedVac, USA). Lipids were
then resuspended in 200 μl of 100% acetonitrile and trans-
ferred to an amber glass vial for LC/MS analysis.
LC/MS assay was carried out using a Shimadzu LC system
equipped with a binary gradient pump, auto-sampler, column
oven, and diode array detector, coupled with a Shimadzu
LCMS 8060 triple quadrupole mass spectrometer (Kyoto,
Japan). Gradient elution involved a mobile phase consisting
of (A) 0.1% formic acid in water and (B) 0.1% formic acid in
acetonitrile. The initial condition was set at 5% of (B), gradi-
ent up to 100% in 10 min and returning to initial condition for
5 min. Oven temperature was set at 40 °C and flow rate was
set at 250 μl/min. For all experiments, 2 μl of samples was
injected. The column used for the separation was a reversed-
phase Zorbax SB18, 50 × 2.0 mm, 3.5 μm (Agilent
Technologies, USA). The ESI/MS was acquired in the posi-
tive and negative ion mode. Product ions of m/z range from
100 to 800 were collected. The drying gas and nebulizer ni-
trogen gas flow rates were 10 l/min and 1.5 l/min respectively.
The DL temperature was °C and BH temperature was 400 °C.
The LC/MS data were peak-detected and noise reduced, such
that only true analytical peaks were further processed. A list of
the intensities of the peaks detected was then generated man-
ually and tabulated into Microsoft Excel for each sample run,
using the retention tine (RT) and m/z data pairs as the identi-
fier for each peak. The ion intensities for each peak detected
were normalized within each sample, to the sum of the peak
intensities in that sample. Differences in the amount of lipid
species present were normalized to total amount of lipids in
each sample and analyzed using one-way ANOVA or two-




Six adult male Wistar rats were used per treatment group
(vehicle control, Alox15 inhibitor, scrambled sense oligo-
nucleotide, and Alox15 antisense oligonucleotide) in this
portion of the study. Rats underwent in vivo electrophys-
iology testing 1 day after intracortical injection (for inhib-
itor studies) and 4 days after intracortical injection (for
antisense studies). The in vivo electrophysiology proce-
dure was conducted as described previously [34]. Rats
were anesthetized with urethane (Sigma-Aldrich) and
mounted on a stereotaxic frame (Stoelting). Urethane
was freshly prepared in sterile isotonic saline (0.9% sodi-
um chloride solution) before use, at a concentration of
1 g/kg body weight. Body temperature was maintained
at 37 °C by a homeothermic blanket. A midline incision
was made on the scalp and small craniotomies performed
using a burr over the sites of insertion of the electrodes. A
bipolar nichrome wire stimulating electrode was placed in
the CA1/subicular region of the temporal hippocampus
(6.3 mm posterior and 5.5 mm lateral to the bregma). A
monopolar stainless steel recording electrode (SNE-300,
David Kopf Instruments, Tujunga, USA) with a recording
tip of diameter 100 μm and length 250 μm was placed in
the prelimbic area of the prefrontal cortex (3.3 mm ante-
rior and 0.9 mm lateral to the bregma). Coordinates were
determined by reference to the atlas of Paxinos and
Watson 1998 [31].
Stimulation of the CA1/subicular region of the hip-
pocampus resulted in characteristic monosynaptic
negative-going field potential recorded from the prefron-
tal cortex, with a latency of 18–24 ms. The depths of
the stimulating and recording electrodes (5.8–7.2 mm












































































Fig. 1 a Differential expression of Alox5, Alox12, and Alox15 mRNA
in the cortex of adult Wistar rats. Anatomically, cortex 1 contains the
primary and secondary motor cortex and the primary somatosensory
cortex, whereas cortex 2 includes the parietal association cortex and
secondary auditory cortex. b Differential expression of Alox15 mRNA
in the CNS of adult Wistar rats in the olfactory bulb, prefrontal cortex,
cortex, striatum, hippocampus, thalamus, cerebellum, brainstem, and
spinal cord. Asterisks indicate significant differences relative to
cerebellum at *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA
with Bonferroni post hoc test. Abbreviations: OB olfactory bulb, PFC
prefrontal cortex, CTX1 cortex 1, CTX2 cortex 2, STR striatum, HC
hippocampus, CX cerebral cortex, SE septum, ST striatum, HC
hippocampus, TH thalamus, CB cerebellum, BS brainstem, SC(C)
cervical region of spinal cord, SC(L) lumbar region of spinal cord
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were adjusted to maximize the amplitude of negative-
going peak of the evoked response. During the initial
localization of the response, stimulation at varying in-
tensities (between 200 and 350 μA) was delivered once
every 15 s. Once an appropriate response was
established, a period of 10 min was given to allow for
response stabilization. The stimulus intensity required to
evoke a response that was 70% of the maximal response
was determined via rendering of an input/output curve
(IOC) and used during the protocol. The stimulation
protocol used for the experiment is as follows: baseline
recording was performed once every 30 s for 30 min at
the stimulus intensity determined by the IOC. High-
frequency stimulation (HFS) was then delivered (50
pulses at 250 Hz, 4 ms interval between pulses). This
sequence was repeated 10 times. After HFS, baseline
stimulation was resumed, and recording was continued
for at least 90 min. Five-minute averages of the ampli-
tude were calculated for further analysis, and the aver-
age field excitatory post-synaptic potentials (fEPSP)
expressed as mean percentage ± SEM normalized to
baseline for each experiment. Differences between
fEPSP (%) recorded for each treatment group were an-
alyzed using repeated measures two-way ANOVA.
P < 0.05 was considered significant.
Rewarded Alternation in a T-Maze
Six adult male Wistar rats were used per group (vehicle
control, Alox15 inhibitor, scrambled sense oligonucleo-
tide, and Alox15 antisense oligonucleotide) in this por-
tion of the study. The T-maze rewarded alternation test-
ing procedure was conducted as previously described
[35]. Rats were habituated for 5 days and trained for
a further 5 days to alternate in the maze in order to
obtain a food reward. On day 11, rats underwent
intracortical injection of vehicle control, Alox15 inhibi-
tor, scrambled sense oligonucleotide, or Alox15 anti-
sense oligonucleotide in a blinded manner. They were
subsequently tested on the T-maze. Differences in the
number of correct options (entry into previously
unentered arm) were analyzed using the two-tailed un-
paired Student’s t test. P < 0.05 was considered
significant.




















































Fig. 2 a Western blot of differential expression of Alox15 protein
expression in the CNS of adult Wistar rats in the olfactory bulb,
prefrontal cortex, cortex, striatum, hippocampus, thalamus, cerebellum,
brainstem, and spinal cord. b Densitometric analyzes differential
expression of Alox15 protein expression in the CNS of adult Wistar
rats. Asterisks indicate significant differences relative to cerebellum at
*P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA with
Bonferroni post hoc test. Abbreviations: OB olfactory bulb, PFC
prefrontal cortex, CTX1 cortex 1, CTX2 cortex 2, ST striatum, HC
hippocampus, CX cerebral cortex, SE septum, ST striatum, HC
hippocampus, TH thalamus, CB cerebellum, BS brainstem, SC(C)
cervical region of spinal cord, SC(L) lumbar region of spinal cord
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Results
Real-Time Reverse Transcriptase Polymerase Chain
Reaction
Real-time RT-PCR results showed that Alox15 is the highest-
expressing isoform in the rat cortex, compared to Alox5 and
Alox12. Alox15 mRNA expression was higher than those of
Alox5 and Alox12 in the prefrontal cortex, the primary and
secondary motor cortex, the primary somatosensory cortex,
the parietal association cortex, and secondary auditory cortex
(Fig. 1a).
After normalization to the endogenous control, β-actin, the
relative mRNA expression of Alox15 was determined in each
brain region relative to the area with lowest expression, the
cerebellum. Real-time RT-PCR results indicate that the pre-
frontal cortex exhibits the highest mRNA expression level
with approximately 25-fold greater expression than the cere-
bellum, followed by the parietal association cortex and sec-
ondary auditory cortex with over 15-fold greater expression
than the cerebellum, olfactory bulb with approximately 15-
fold greater expression than the cerebellum, motor and so-
matosensory cortices, and the hippocampus. Higher Alox15
mRNA levels are expressed across the forebrain regions as

















Fig. 3 Immunohistochemical labeling of Alox5 in the forebrain.
Moderately dense staining is observed in the olfactory bulb (a), cerebral
cortex, including the prefrontal cortex (b), septum (c), striatum (d), while
light staining is observed in the hippocampus (e), thalamus (f), and
hypothalamus. Staining is mostly observed as punctuate profiles in the
neuropil in these regions, and cell bodies were mostly unlabeled (g, h).
Abbreviations: OB olfactory bulb, CX cerebral cortex, SE septum, ST
striatum, HC hippocampus, TH thalamus. Scale: a–f = 200 μm. g,

















Fig. 4 Immunohistochemical labeling of Alox5 in the hindbrain and
spinal cord. The cerebellum including the cerebellar cortex (a) and deep
cerebellar nuclei (b) were moderately labeled.Most parts of the brainstem
are lightly labeled, except for the inferior olivary nucleus (c), dorsal and
ventral cochlear nuclei (d), and superficial portion of the spinal trigeminal
nucleus (e). The spinal cord is also lightly labeled, except the substantia
gelatinosa, in the superficial part of the dorsal horn (f). Staining is mostly
observed as punctuate profiles in the neuropil in these regions, and cell
bodies were mostly unlabeled (g, h). Abbreviations: CCX cerebellar
cortex, DN dentate nucleus, IN inferior olivary nucleus, CN cochlear
nucleus, TN spinal trigeminal nucleus, DH dorsal horn of spinal cord
(lumbar region). Arrowheads indicate immunoreaction product in
superior portion of spinal trigeminal nucleus and dorsal horn. Scale: a–
f = 200 μm. g, h = 20 μm
Mol Neurobiol
Western Blot Analysis of Alox15 Protein Expression
in the Brain
The Alox15 antibody detected a single 75 kDa band in the
adult rat brain (Fig. 2a). The 75 kDa band size is consistent
with the predicted 75 kDa Alox15 protein size [6], and to date,
no significant glycosylation of the enzyme has been identified
nor are there any indications of myristoylation or
isoprenylation [36, 37]. Quantification of protein was deter-
mined by densitometric analysis of Alox15 bands normalized
to that of β-actin.
To maintain consistency in comparison across real-time
RT-PCR and Western blot, fold change levels were compared
relative to the cerebellum. The prefrontal cortex was found to
have the highest Alox15 protein expression with levels ap-
proximately 18-fold more than that of the cerebellum, follow-
ed by cortex 1 (13-fold), cortex 2 (12-fold), hippocampus (10-
fold), and olfactory bulb (9-fold). The striatum and thalamus
display relatively lower levels of protein expression while the
hindbrain regions of cerebellum and brainstem and the spinal
cord have low and insignificant levels of Alox15 expression.
Results from the quantitative densitometric analysis of the
Western blots are consistent with those of real-time RT-PCR.
Overall, the prefrontal cortex expresses the highest Alox15
mRNA and protein expression levels relative to the cerebel-
lum, followed by the cerebral cortical areas (Fig. 2b).
Immunohistochemistry
Moderately dense staining was observed in the olfactory bulb
(Fig. 3a), cerebral cortex, including the prefrontal cortex
(Fig. 3b), septum (Fig. 3c), striatum (Fig. 3d), while light
staining was observed in the hippocampus (Fig. 3e), thalamus
(Fig. 3f), and hypothalamus. Staining was mostly observed as
punctuate profiles in the neuropil in these regions, and cell
bodies were mostly unlabeled (Fig. 3g, h).
The cerebellum including the cerebellar cortex (Fig. 4a)
and deep cerebellar nuclei (Fig. 4b) was moderately labeled.
Most parts of the brainstemwere lightly labeled, except for the
inferior olivary nucleus (Fig. 4c), the dorsal and ventral co-
chlear nuclei (Fig. 4d), and the superficial portion of the spinal
trigeminal nucleus (Fig. 4e). The spinal cord was also lightly
labeled, except the substantia gelatinosa, in the superficial part
of the dorsal horn (Fig. 4f). Staining was mostly observed as
punctuate profiles in the neuropil in these regions, and cell
bodies were mostly unlabeled (Fig. 4g, h).
Electron Microscopy
Electron microscopy of immunostained sections of the pre-
frontal cortex showed dense staining of the neuropil. Label
was observed in dendrites or dendritic spines (Fig. 5a, b).
Western Blot Analysis to Confirm Alox15 Knockdown
with Antisense Oligonucleotide
The Alox15 antibody detected a single 75 kDa band in the
adult rat brain (Fig. 6a), consistent with the predicted size of
Alox15 protein. Analyses of normalized density of Alox15
bands to β-actin showed a significant 82% decrease
(P < 0.05) in Alox15 protein levels in antisense-injected rats,
indicating effective knockdown by Alox15 antisense
oligonucleotide.
Liquid Chromatography Mass Spectrometry
LCMS analysis shows a statistically significant decrease in
resolvin D1 levels (P < 0.05) (Fig. 6b) after intracortical in-
jection of Alox15 inhibitor in the prefrontal cortex of the rat
brain.
LCMS analysis shows a statistically significant decrease in
resolvin D1 levels (P < 0.01) (Fig. 6c) after intracortical in-
jection of Alox15 antisense in the prefrontal cortex of the rat






Fig. 5 Electron microscopy of immunostained sections of the prefrontal
cortex showed dense staining of the neuropil. Label was observed in
dendrites or dendrit ic spines (a , b) . Arrowheads indicate




The effects of hippocampal stimulation on LTP induction in
the hippocampo-prefrontal cortex pathway for rats treated
with Alox15 inhibitor and DMSO vehicle control were eval-
uated by in vivo electrophysiology (Fig. 7a). Repeated mea-
sures two-way ANOVA indicated that HFS did induce LTP in
control groups F (24,120) = 12.913, P < 0.001 and also indi-
cated that the treatment (Alox15 inhibitor) exerted a signifi-
cant effect on fEPSPs F(1,10) = 34.759, P < 0.001. Further,
two-tailed Student’s t tests carried out to compare between the
treatment groups showed no significant difference between
fEPSPs of vehicle control and Alox15-injected rats before
HFS, but confirmed a significant (P < 0.001) difference after
HFS, sustained for 90 min post-HFS (Fig. 7b). This indicates
that intracortical injection of Alox15 inhibitor prevented in-
duction of LTP along the hippocampo-prefrontal cortex
pathway.
These results were confirmed with intracortical injec-
tion of Alox15 antisense oligonucleotides and scrambled
sense control (Fig. 8a.) Repeated measures two-way
ANOVA indicated that HFS did induce LTP in control
groups F (24,120) = 26.315, P < 0.001 and also indi-
cated that the treatment (Alox15 antisense) exerted a
significant effect on fEPSP F(1,10) = 156.178,
P < 0.001. Further, two-tailed Student’s t tests carried
out to compare between the treatment groups showed no
significant difference between fEPSPs of scramble sense
and Alox15 antisense rats before HFS, but confirmed a
significant (P < 0.001) difference after HFS, sustained
for 90 min post-HFS (Fig. 8b). This confirms that ge-
netic knockdown of Alox15 prevented induction of LTP
along the hippocampo-prefrontal cortex pathway.
Rewarded Alternation in T-Maze
Performance of rats in the rewarded alternation task in
the T-maze was measured by the total number of correct
responses (entry into previously unentered arm) made
by a rat during the 5 training days and 3 testing days.
Rats in the Alox15 and vehicle control groups per-
formed equally well on training days 1–5. On testing
day 1 (1 day after intracortical injection), rats injected
with Alox15 inhibitor made significantly (P < 0.001)
more errors than vehicle-injected controls. On testing
days 2 and 3, performance of inhibitor-injected rats re-
covered to the same level as vehicle-injected controls
(Fig. 9a).
Similarly, rats in the Alox15 antisense and scrambled
sense control groups performed equally well on training






















































Fig. 6 aWestern blot of effect of
Alox15 oligonucleotide treatment
on Alox15 protein expression in
the rat prefrontal cortex. b LCMS
analysis of effect of Alox15
inhibitor treatment on resolvin D1
levels in the rat prefrontal cortex.
c LCMS analysis of effect of
Alox15 oligonucleotide treatment
on resolvin D1 levels in the rat
prefrontal cortex. Asterisk (*)
indicate significant differences at
P < 0.05, two-tailed Student’s t
test. Asterisks (**) indicate




days 1–5, while rats injected with Alox15 antisense ol-
igonucleotide made significantly (P < 0.001) more er-
rors than scrambled sense injected controls on testing
days 2 and 3, which corresponds with the time taken
for the antisense oligonucleotide to knock down protein
expression (Fig. 9b). This confirms that the Alox15 en-
zyme in the prefrontal cortex is essential for spatial
working memory.
Discussion
The expression levels of reticulocyte-type Alox15 across
the CNS were studied via real-time RT-PCR and Western
blot. Real-time RT-PCR results indicate that Alox15
mRNA is present across all 11 different brain regions
studied, with the olfactory bulb, prefrontal cortex, cere-
bral cortices, and the hippocampal regions displaying sig-
nificant levels of expression while the hindbrain regions
such as the brain stem and the spinal cord express non-
significant low mRNA levels. Comparison with other
lipoxygenases shows that Alox15 is the highest-
expressing isoform in the rat cortex, compared to Alox5
and Alox12. Protein expression levels exhibited by
Western blot were largely consistent with the results of
real-time RT-PCR. The prefrontal cortex displays the
highest mRNA and protein levels relative to the cerebel-
lum, but various parts of the hindbrain and the spinal cord
display almost non-quantifiable protein levels of Alox15
relative to the cerebellum in Western blot. Tissue locali-
zation via immunohistochemistry supported the results of
real-time RT-PCR and Western blot. The olfactory bulb,
septum, cerebral cortex, striatum, and cerebellar cortex
showed moderate Alox15 staining. The distinct patterns
of relative distribution and localization as elucidated by
this investigation may provide insight into the roles of
Alox15 in synaptic plasticity and neurodegenerative dis-
eases. The high level of expression of Alox15 in the pre-
frontal cortex suggests that the enzyme may play an im-
portant role in functions such as synaptic plasticity and
learning and memory. The brainstem and spinal cord
showed light staining, except the inferior olivary nucleus,
and some of the sensory nuclei such as the dorsal and
ventral cochlear nuclei, the spinal trigeminal nucleus,
and the dorsal horn of the spinal cord. In both the spinal
trigeminal nucleus and the dorsal horn of the spinal cord,
staining is found in the entry zone of primary afferents,
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Fig. 7 a Effects of hippocampal
stimulation on fEPSP in
prefrontal cortex. Data points
represent mean fEPSP over the
preceding 5 min. Error bars
represent SEM. n = 6 for all
treatment groups. Alox15
inhibitor treatment has a
significant effect on fEPSP.
F(1,10) = 34.759, P < 0.001.
Repeated measures two-way
ANOVA. b DMSO control vs
Alox15 inhibitor. Columns
representmean normalized fEPSP
over the preceding 30 min.
Asterisks (***) indicate
significant differences at P < 0.05,
two-tailed Student’s t test
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role of Alox15 product, resolvin D1 in antinociception
[38–40].
We next studied the functional role of Alox15 in prefrontal
cortex, a region that showed high level of gene expression by
RT-PCR, Western blot, and immunohistochemistry. In this
study, we showed that Alox15 inhibition/knockdown resulted
in a decrease in resolvin D1 levels. Resolvin D1 has been
shown to be a potent inhibitor for inflammatory pain [38]
and also blocks TNFα-induced IL-1β transcripts and regu-
lates PMN infiltration in brain [11]. In addition, resolvin D1
has been shown to alter synaptic plasticity in the mouse spinal
cord [38]. Given the potential role of RvD1 in synaptic plas-
ticity, the effects of Alox15 inhibition/knockdown on in the
prefrontal cortex were investigated using LTP, a model of
synaptic plasticity underlying learning. The prefrontal cortex
and hippocampus are functionally related due to projections
from the CA1 region of the hippocampus to the medial and
orbital prefrontal cortex [41]—forming the hippocampo-
prefrontal cortex pathway, a possible pathway via which spa-
tial information is integrated in cognitive functions and goal
directed motor behavior [42, 43]. Induction of LTP in the
hippocampo-prefrontal cortex pathway is characterized by
an increase in the amplitude of the evoked excitatory post-
synaptic field potential (fEPSP) recorded in the prefrontal
cortex upon administration of a HFS to the hippocampus
[44]. We observed that injection of an inhibitor or antisense
oligonucleotide to Alox15 successfully prevented LTP induc-
tion in the hippocampo-prefrontal cortex pathway. The anti-
sense knockdown of Alox15 was further corroborated by
Western blot analysis showing a significant decrease in
Alox15 protein expression in the prefrontal cortex after
injection.
In view of the abovementioned effects of Alox15
inhibition/knockdown on LTP in the hippocampo-prefrontal
cortex pathway, we postulated that Alox15 could be essential
for spatial working memory, which is dependent on the path-
way. Spatial working memory acts to maintain memory of the
spatial information of an object, stimulus association, or loca-
tion within a specific test session but not between sessions
[45]. Rodents have a natural tendency to alternate their choice
of goal arm in a T-maze task, which reflects an adaptation to
efficiently locate resources such as food, water, and shelter in
their natural environment [46] and provision of a food reward
increases the motivation to perform the task [47]. Rats that
received Alox15 inhibitor or Alox15 antisense oligonucleo-
tide injection in the prefrontal cortex showed poor perfor-
mance in the rewarded alternation in T-maze task compared
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Fig. 8 a Effects of hippocampal
stimulation on fEPSP in
prefrontal cortex. Data points
represent mean fEPSP over the
preceding 5 min. Error bars
represent SEM. n = 6 for all
treatment groups. Alox15
oligonucleotide treatment has a
significant effect on fEPSP. F
(1,10) = 156.178, P < 0.001.
Repeated measures two-way
ANOVA. b Scrambled sense
control vs Alox15 antisense
oligonucleotide. Columns
representmean normalized fEPSP
over the preceding 30 min.
Asterisks (***) indicate
significant differences at P < 0.05,
two-tailed Student’s t test
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prefrontal cortex pathway has been observed previously by
examining performance in a delayed radial maze task, after
unilateral lesion of the ventral subiculum in combination with
a contralateral lesion of the prefrontal cortex. These combined
lesions produced a disruption of foraging only during the test
phase of this delayed win-shift task, similar to that described
after bilateral inactivation of the prelimbic area [48], suggest-
ing that transmission of information between the hippocampus
and the prefrontal cortex is required when task-specific short-
term memory is used to facilitate search behavior [42]. The
present findings of an important role of Alox15 in prefrontal
cortical function adds to our recent results that show Alox15
plays a role in supraspinal antinociception originating in the
prefrontal cortex [12].
Electron microscopic analysis revealed immunolocaliza-
tion of Alox15 at dendrites, which is consistent with a role
in synaptic plasticity in the prefrontal cortex. NMDA recep-
tors are important for induction of many forms of LTP includ-
ing LTP in the hippocampo-prefrontal cortex pathway [49].
DHA, the major substrate of Alox15 in production of resolvin
D1, has been reported to increase expression of NMDA re-
ceptor subunits important for synaptic plasticity and memory
[50, 51]. Consistent with the role of PUFAs, including DHA,
in promoting NMDA receptor subunit expression and induc-
tions of LTP, dietary omega-3 deficiency reduces BDNF con-
tent and activation of NMDA receptors in the rat hippocampus
[52]. In comparison, dietary enrichment with omega-3
PUFAs, including DHA, was also reported to reverse age-
related decreases in the GluR2 and NR2B glutamate receptor
subunits in the rat forebrain [53].
Intrathecal RvD1 has been shown to block mechanical
hyperalgesia and allodynia [54, 55]. The effect of RvD1 in
inhibiting neuropathic pain points to a central mechanism in-
volving changes in neuroplasticity. RvD1 could mediate its
effects on neuroplasticity through binding with known
RvD1 receptors formyl-peptide receptor 2 (FPR2) and G
protein-coupled receptor 32 (GPR32) [56]. Although GPR32
is a pseudogene in rats, the binding of RvD1 to GPR32 has
been documented in humans to attenuate inflammation-

































































































































AFig. 9 a Percentage correct
responses made during T-maze
procedure, DMSO control vs.
Alox15 inhibitor. b Percentage
correct responses made during T-
maze procedure, Alox15
antisense oligonucleotide vs
scrambled sense control. Asterisks
(***) indicate significant
differences at P < 0.05, two-tailed
Student’s t test
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TNF release [55, 57]. Activation of the G protein-coupled
receptors FPR2 and GPR32 by RvD1 in the central sensory
pathway may alter synaptic transmission [54, 55], and one
study has indicated transient receptor potential ion channel
vanilloid 3 (TRPV3) as a molecular target for RvD1 [58].
In conclusion, the current findings indicate that Alox15 pro-
cessing of DHA contributes to production of resolvin D1 and
LTP at hippocampo-prefrontal cortex synapses and associated
spatial working memory performance. Our findings point to the
role of anti-inflammatory molecules such as resolvin D1 in
neuroplasticity and brain signaling, and possible disturbances in
this system under conditions of neuroinflammatory brain disor-
ders and chronic neurodegeneration.
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